<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04687098</url>
  </required_header>
  <id_info>
    <org_study_id>AML-12</org_study_id>
    <nct_id>NCT04687098</nct_id>
  </id_info>
  <brief_title>Risk-adapted Therapy for Primary Acute Myeloid Leukemia</brief_title>
  <official_title>Risk-adapted Therapy for Primary Acute Myeloid Leukemia (AML) in Adult Patients up to 70 Years Old</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The AML-12 study investigates the efficacy and toxicity of standard induction chemotherapy&#xD;
      with idarubicin and cytarabine (IC) with G-CSF priming followed by a risk-adapted post&#xD;
      remission therapy for patients up to the age of 70 diagnosed with de novo acute myeloid&#xD;
      leukemia (AML).&#xD;
&#xD;
      Modifications from the previous protocol AML-03 (NCT01723657) include removal of etoposide in&#xD;
      induction, limitation of the GCSF priming to the induction phase and categorization of post&#xD;
      remission therapy (stem cell transplant or 2 high dose cytarabine consolidations) according&#xD;
      to diagnostic genetics as well as post-remission clearance of measurable residual disease.&#xD;
&#xD;
      The aims of these modifications are to improve the overall survival and leukemia free&#xD;
      survival of acute myeloid leukemia patients with a risk-adapted approach.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Induction chemotherapy: Idarubicin (12mg/m2/day intravenous, days 1-3), Low-dose cytarabine&#xD;
      (200mg/m2/day, intravenous in continuous infusion, days 1-7) and G-CSF priming 150mcg/m2/day,&#xD;
      subcutaneous from day 0 to the last day of chemotherapy if white blood cell count (WBC)&#xD;
      &lt;30x10E9/L.&#xD;
&#xD;
      This induction chemotherapy can be repeated twice in the case of partial response (PR) to&#xD;
      achieve complete response (CR).&#xD;
&#xD;
      Once CR is achieved (with one or two induction cycles), all patients receive a consolidation&#xD;
      course with high-dose cytarabine (3000mg/m2/12h days 1, 3 and 5) and pegfilgrastim 6mg on day&#xD;
      6.&#xD;
&#xD;
      After this, patients will be allocated to the different risk groups as follows:&#xD;
&#xD;
        -  Favorable risk group [patients with t(8;21)(q22;q22)/RUNX1/RUNX1T1, inv(16)(p12;q22) or&#xD;
           t(16;16)/CBFB/MYH11; Intermediate risk cytogenetics (MRC 2010) and NPM1 mutation with&#xD;
           FLT3 wild type or low ratio of FLT3 internal tandem duplication (ITD)/wild type (&lt;0.5);&#xD;
           or CEBPA biallelic mutation]. Patients in this group will receive 2 additional courses&#xD;
           of consolidation therapy&#xD;
&#xD;
        -  Intermediate risk group [Intermediate risk cytogenetics (MRC 2010) without NPM1&#xD;
           mutations, FLT3-ITD, or CEBPA biallelic mutation]. Patients in this group receive an&#xD;
           allogeneic stem cell transplant in first CR. Patients without an available donor can be&#xD;
           autografted per center decision&#xD;
&#xD;
        -  Adverse risk group [Adverse risk cytogenetics (MRC 2010), intermediate cytogenetics with&#xD;
           FLT3-ITD without NPM1 mutation or NPM1-FLT3-ITD high ratio or MLL rearrangement; any&#xD;
           favorable or intermediate risk patients with positive MRD following 1 (intermediate) or&#xD;
           2 (favorable) consolidation courses]. Intention to treat of those patients is allogeneic&#xD;
           stem cell transplant from any source.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2012</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete remission rate (CRR)</measure>
    <time_frame>2 months</time_frame>
    <description>Analyze the efficacy and toxicity of the current doses of IC (Idarubicin and cytarabine) with G-CSF priming to achieve complete remission in patients tih AML up to 70yo.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Disease free survival (DFS)</measure>
    <time_frame>4 years</time_frame>
    <description>Analyze the disease free survival in the whole cohort of AML patients.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Relapse rate (RR)</measure>
    <time_frame>4 years</time_frame>
    <description>Analyze the relapse rate of all patients achieving remission with intensive induction followed by risk-adapted consolidation strategies.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Feasibility of treatment completion</measure>
    <time_frame>4 years</time_frame>
    <description>Increase the number of patients who complete all treatment phases</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival outcome analysis of the 3 risk-adapted categories (favourable, intermediate and adverse)</measure>
    <time_frame>4 years</time_frame>
    <description>Evaluate the feasibility of the consolidation treatments in the different risk groups by comparison of overall survival (OS), RR and DFS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Feasibility of centralized monitoring of measurable residual disease (MRD)</measure>
    <time_frame>4 years</time_frame>
    <description>Survival outcomes in positive vs negative MRD patients. Number of patients with modified risk due to positive MRD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of global outcomes with previous protocol (AML-03) and other published protocols.</measure>
    <time_frame>4 years</time_frame>
    <description>Comparison of CRR, OS, RR and DFS</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Leukemia, Myeloid, Acute</condition>
  <arm_group>
    <arm_group_label>Risk-adapted postremission treatment.</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Induction (idarubicin, cytarabine), first consolidation (high dose cytarabine), risk- stratification: allogeneic matched related or unrelated donor transplant vs. consolidation courses.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Idarubicin</intervention_name>
    <description>12 mg/m2/day; intravenous, administration at induction phase, days 1 to 3.</description>
    <arm_group_label>Risk-adapted postremission treatment.</arm_group_label>
    <other_name>Ida</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ara-C</intervention_name>
    <description>200mg/m2/day, intravenous at induction phase; days 1-7.&#xD;
- High dose during consolidation phase. In patients up to 60 years 3g/m2/12hours days 1,3,5, and patients 60 to 70 years: 1.5g/m2/12hours days 1,3,5.</description>
    <arm_group_label>Risk-adapted postremission treatment.</arm_group_label>
    <other_name>HDAC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>G-CSF</intervention_name>
    <description>Administration at induction phase to remission days 1 to 7. G-CSF will not be initiated if the leukocyte count is over 30x10e9/L at diagnosis or will be interrupted if the leukocyte count during treatment arises 30x10e9/L.&#xD;
Administration at consolidation phase day 7.</description>
    <arm_group_label>Risk-adapted postremission treatment.</arm_group_label>
    <other_name>Pegfilgrastim</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Allogeneic matched or unrelated donor transplant.</intervention_name>
    <description>To be performed in patients in the intermediate or adverse risk groups.</description>
    <arm_group_label>Risk-adapted postremission treatment.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Autologous peripheral blood stem cell transplant</intervention_name>
    <description>To be considered in patients in the intermediate risk group without an available allogeneic donor and negative measurable residual disease, per center decision.</description>
    <arm_group_label>Risk-adapted postremission treatment.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Measurable residual disease</intervention_name>
    <description>To be performed either with molecular monitoring or, if not applicable, by flow cytometry. Pre-stablished cut-off values are defined for decision-making.</description>
    <arm_group_label>Risk-adapted postremission treatment.</arm_group_label>
    <other_name>MRD</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with newly diagnosed AML, classified using the World Health Organization&#xD;
             (WHO) 2017 criteria.&#xD;
&#xD;
          -  Patients with 70 years old or younger.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients previously treated for the AML with chemotherapy different from hydroxyurea.&#xD;
&#xD;
          -  Acute promyelocytic leukemia with t(15;17).&#xD;
&#xD;
          -  Chronic myeloid leukemia in blastic phase.&#xD;
&#xD;
          -  Secondary AML or therapy related AML.&#xD;
&#xD;
          -  Presence of concomitant active neoplastic disease.&#xD;
&#xD;
          -  Abnormal renal and hepatic functions with creatinin and/or bilirubin 2 times higher&#xD;
             than the normal threshold, except when the alteration should be attributed to the&#xD;
             leukemia.&#xD;
&#xD;
          -  Patients with a cardiac ejection fraction below 45%, symptomatic cardiac deficiency or&#xD;
             both.&#xD;
&#xD;
          -  Patients with neurological or concomitant psychiatric disease.&#xD;
&#xD;
          -  HIV infection.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>17 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jorge Sierra, Prof, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jordi Esteve, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clinic of Barcelona</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jorge Sierra, Prof, MD</last_name>
    <phone>+34935565649</phone>
    <phone_ext>5649</phone_ext>
    <email>jsierra@santpau.cat</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ana Garrido, MD</last_name>
    <phone>+34935565649</phone>
    <phone_ext>5649</phone_ext>
    <email>agarridod@santpau.cat</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>ICO Badalona-Hospital Universitari Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Josep M Ribera, MD</last_name>
      <phone>+34 934978924</phone>
      <phone_ext>8995</phone_ext>
      <email>jribera@iconcologia.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>ICO Hospital Universitari de Bellvitge</name>
      <address>
        <city>Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Montserrat Arnan, MD</last_name>
      <phone>+34 932607553</phone>
      <phone_ext>7553</phone_ext>
      <email>marnan@iconcologia.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Son Espases</name>
      <address>
        <city>Palma de Mallorca</city>
        <state>Mallorca</state>
        <zip>07198</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonia Sampol, MD</last_name>
      <email>antonia.sampolm@ssib.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Son Llatzer</name>
      <address>
        <city>Palma de Mallorca</city>
        <state>Mallorca</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joan Bargay, MD</last_name>
      <email>jbargay@hsll.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Verge de la Cinta</name>
      <address>
        <city>Tortosa</city>
        <state>Tarragona</state>
        <zip>43517</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Llorenç Font, MD</last_name>
      <phone>+34 977519100</phone>
      <email>lfont.ebre.ics@gencat.cat</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carmen Pedro, MD</last_name>
      <phone>+34 932483341</phone>
      <phone_ext>3341</phone_ext>
      <email>mpedro@parcsalutmar.cat</email>
    </contact>
    <contact_backup>
      <last_name>Brayan Marcel Merchan, MD</last_name>
      <email>bmmerchan@parcdesalutmar.cat</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jorge Sierra, MD</last_name>
      <phone>+34 93 2919050</phone>
      <phone_ext>5649</phone_ext>
      <email>jsierra@santpau.cat</email>
    </contact>
    <contact_backup>
      <last_name>Ana Garrido, MD</last_name>
      <phone>+34 93 2919050</phone>
      <phone_ext>5649</phone_ext>
      <email>agarridod@santpau.cat</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hospital Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+34 932746000</phone>
      <phone_ext>6616</phone_ext>
    </contact>
    <contact_backup>
      <last_name>Olga Salamero, MD</last_name>
      <email>osalamero@vhebron.net</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jordi Esteve, MD</last_name>
      <phone>+34932275400</phone>
      <phone_ext>5719</phone_ext>
      <email>jesteve@clinic.ub.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>ICO-Girona Hopital Universitari de Girona Dr. Josep Trueta</name>
      <address>
        <city>Girona</city>
        <zip>17007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Gallardo, MD</last_name>
      <phone>+34 972940200</phone>
      <phone_ext>263</phone_ext>
      <email>dgallardo@iconcologia.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Arnau de Vilanova</name>
      <address>
        <city>Lleida</city>
        <zip>25006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antoni Garcia, MD</last_name>
      <phone>+34 973248100</phone>
      <email>agarcia@arnau.scs.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de la Victoria</name>
      <address>
        <city>Malaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>M Paz Queipo, MD</last_name>
      <phone>+34 951032000</phone>
      <email>hematologia.planta.hvv.sspa@juntadeandalucia.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>ICO Tarragona-Hospital Universitari Joan XXIII</name>
      <address>
        <city>Tarragona</city>
        <zip>43007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carme Talarn, MD</last_name>
      <phone>+34 977295800</phone>
      <phone_ext>5821</phone_ext>
      <email>ctalarn@iconcologia.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mutua de Terrassa</name>
      <address>
        <city>Terrassa</city>
        <zip>08225</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ferran Vall-Llovera, MD</last_name>
      <phone>+34 937365050</phone>
      <phone_ext>5026</phone_ext>
      <email>fvall_llovera@mutuaterrassa.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>496010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mar Tormo, MD</last_name>
      <phone>+3493862600</phone>
      <email>tormo_mar@gva.es</email>
    </contact>
    <investigator>
      <last_name>Mar Tormo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>December 18, 2020</study_first_submitted>
  <study_first_submitted_qc>December 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 29, 2020</study_first_posted>
  <last_update_submitted>July 30, 2021</last_update_submitted>
  <last_update_submitted_qc>July 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Leukemia</keyword>
  <keyword>Myeloid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Idarubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

